Biocure Technology Inc. announced the formation of a new advisory committee who will support management in advancing the company. The company appointed the members, Jae Soo Shin, Heon Ju Lee and Hyun Soo Lee to the Bio cure team. Their combined expertise and experience will be a great asset in advancing the company and helping bridge the business in Korea to North America.

New advisory board members JAE SOO has worked as a chief of pharmacology &toxicology Lab. in the preclinical development of new drugs in Chong Kun Dang Pharmaceutical Corp. for 21 years.

Since 2008, he has been working as a managing director for IL-YANG Pharm. Co. Ltd., being responsible for preclinical and clinical development of new drugs and several vaccines for human and avian influenza.

Since 2013, he has also been a member of policy advisory committee of KSAP. HEON JU LEE is the vice-president of BiocurePharm, leading the pre-clinical and clinical development of biopharmaceuticals such as interferon beta and CAR-T immune cell therapy products. HYUN SOO LEE is currently director of research institute of Pharos Vaccine Inc. and a non-executive director of Aprogen Inc. The company also announced the appointment of Sang Goo Kim as the company's Chief Financial Officer and corporate secretary.

Mr. Kim replaces Nizar Bharmal as Chief Financial Officer.